Christoph Nowak
Chief Tech/Sci/R&D Officer at DIAMYD MEDICAL AB
Net worth: 581 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Anders Essen-Möller | M | 83 | 28 years | |
Markus Jerling | M | 72 | 3 years | |
Ulf Hannelius | M | 49 | 8 years | |
Erik Kjellsson Nerpin | M | 63 | 12 years | |
Daniel Ehrenstråhle | M | 50 | 1 years | |
Mark Atkinson | M | 63 | 6 years | |
Martina Widman | F | 43 | 8 years | |
Niclas Holmgren | M | 32 | 1 years | |
Karin Hehenberger | M | 52 | 3 years | |
Carl Torbjörn Bäckström | M | 76 | 7 years | |
Michael Owens | M | 68 | 1 years | |
Anna Styrud | F | 63 | 14 years | |
Theresa Comiskey Olsen | F | 61 |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | - |
Maria-Teresa Essen-Möller | F | 54 | 15 years | |
Anton Lindqvist | M | 44 | 11 years | |
Karin Rosen | M | 57 | 1 years | |
Eva Karlström | F | 60 | 4 years | |
Stian Kildal | M | - | 1 years | |
Kristofer Svensson | M | - |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | 2 years |
Lars Christer Fedrik Fåhraeus | M | 59 |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paul de Potocki | M | 62 | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
Sweden | 21 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christoph Nowak
- Personal Network